| 产品名称： | HCC2218 |
|---|---|
| 商品货号： | TS212044 |
| Organism： | Homo sapiens, human |
| Tissue： | mammary gland; breast/duct |
| Cell Type： | Epithelial,lymphoblast |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | suspension, The cells grow as floating aggregates of large cell clusters. |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | TNM stage IIIA, grade 3,primary ductal carcinoma |
| Age： | 38 years adult |
| Gender： | female |
| Ethnicity： | Caucasian, White |
| Storage Conditions： | liquid nitrogen vapor phase |
| Karyotype： | polyploid |
| Images： |  |
| Derivation： | HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient. The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish. HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes. |
| Clinical Data： | 38 years
Caucasian, White
female
|
| Oncogene： | her2/neu +, p53 + |
| Genes Expressed： | Epithelial glycoprotein 2 EGP2; cytokeratin 19 |
| Cellular Products： | Epithelial glycoprotein 2 EGP2; cytokeratin 19 |
| Comments： | The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.xa0 HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 EGP2 and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER -). An EBV transformed lymphoblastoid cell line HCC2218 BL from the same patient is available as ATCC CRL-2363.
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| Name of Depositor： | AF Gazdar, AK Virmani |
| Year of Origin： | 1996 |
| References： | Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | HCC2218 |
|---|---|
| 商品货号： | TS212044 |
| Organism： | Homo sapiens, human |
| Tissue： | mammary gland; breast/duct |
| Cell Type： | Epithelial,lymphoblast |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | suspension, The cells grow as floating aggregates of large cell clusters. |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | TNM stage IIIA, grade 3,primary ductal carcinoma |
| Age： | 38 years adult |
| Gender： | female |
| Ethnicity： | Caucasian, White |
| Storage Conditions： | liquid nitrogen vapor phase |
| Karyotype： | polyploid |
| Images： | |
| Derivation： | HCC2218 was derived from a female whose family members included several members with cancer; four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient. The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish. HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes. |
| Clinical Data： | 38 years
Caucasian, White
female
|
| Oncogene： | her2/neu +, p53 + |
| Genes Expressed： | Epithelial glycoprotein 2 EGP2; cytokeratin 19 |
| Cellular Products： | Epithelial glycoprotein 2 EGP2; cytokeratin 19 |
| Comments： | The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.xa0 HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 EGP2 and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER -). An EBV transformed lymphoblastoid cell line HCC2218 BL from the same patient is available as ATCC CRL-2363.
The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53.
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| Name of Depositor： | AF Gazdar, AK Virmani |
| Year of Origin： | 1996 |
| References： | Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771 |
